Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study by Dackus, Gwen Mhe et al.
 1Dackus GMHE, et al. BMJ Open 2017;7:e017842. doi:10.1136/bmjopen-2017-017842
Open Access 
Long-term prognosis of young breast 
cancer patients (≤40 years) who did not 
receive adjuvant systemic treatment: 
protocol for the PARADIGM initiative 
cohort study
Gwen MHE Dackus,1,2 Natalie D ter Hoeve,2 Mark Opdam,1 Willem Vreuls,3 
Zsuzsanna Varga,4 Esther Koop,5 Stefan M Willems,2 Carolien HM Van Deurzen,6 
Emilie J Groen,7 Alicia Cordoba,8 Jos Bart,9 Antien L Mooyaart,10 
Jan G van den Tweel,2 Vicky Zolota,11 Jelle Wesseling,7 Anna Sapino,12,13 
Ewa Chmielik,14 Ales Ryska,15 Frederic Amant,16 Annegien Broeks,17 
Ron Kerkhoven,18 Nikolas Stathonikos,2 Mitko Veta,19 Adri Voogd,20,21 
Katarzyna Jozwiak,22 Michael Hauptmann,22 Marlous Hoogstraat,23 
Marjanka K Schmidt,1,24 Gabe Sonke,25 Elsken van der Wall,26 Sabine Siesling,21,27 
Paul J van Diest,2 Sabine C Linn1,2,25
To cite: Dackus GMHE, ter 
Hoeve ND, Opdam M, et al.  
Long-term prognosis of young 
breast cancer patients (≤40 
years) who did not receive 
adjuvant systemic treatment: 
protocol for the PARADIGM 
initiative cohort study. BMJ Open 
2017;7:e017842. doi:10.1136/
bmjopen-2017-017842
 ► Prepublication history and 
additional material for this paper 
are available online. To view, 
please visit the journal (http:// 
dx. doi. org/ 10. 1136/ bmjopen- 
2017- 017842).
PJD and SCL contributed 
equally.
Received 19 May 2017
Revised 15 August 2017
Accepted 20 September 2017
For numbered affiliations see 
end of article.
Correspondence to
Dr Sabine C Linn;  s. linn@ nki. nl
Protocol
AbstrACt
Introduction Currently used tools for breast cancer 
prognostication and prediction may not adequately reflect 
a young patient’s prognosis or likely treatment benefit 
because they were not adequately validated in young 
patients. Since breast cancers diagnosed at a young 
age are considered prognostically unfavourable, many 
treatment guidelines recommend adjuvant systemic 
treatment for all young patients. Patients cured by 
locoregional treatment alone are, therefore, overtreated. 
Lack of prognosticators for young breast cancer patients 
represents an unmet medical need and has led to the 
initiation of the PAtients with bReAst cancer DIaGnosed 
preMenopausally (PARADIGM) initiative. Our aim is to 
reduce overtreatment of women diagnosed with breast 
cancer aged ≤40 years.
Methods and analysis All young, adjuvant systemic 
treatment naive breast cancer patients, who had no prior 
malignancy and were diagnosed between 1989 and 2000, 
were identified using the population based Netherlands 
Cancer Registry (n=3525). Archival tumour tissues were 
retrieved through linkage with the Dutch nationwide 
pathology registry. Tissue slides will be digitalised 
and placed on an online image database platform for 
clinicopathological revision by an international team of 
breast pathologists. Immunohistochemical subtype will 
be assessed using tissue microarrays. Tumour RNA will 
be isolated and subjected to next-generation sequencing. 
Differences in gene expression found between patients 
with a favourable and those with a less favourable 
prognosis will be used to establish a prognostic classifier, 
using the triple negative patients as proof of principle.
Ethics and dissemination Observational data from the 
Netherlands Cancer Registry and left over archival patient 
material are used. Therefore, the Dutch law on Research 
Involving Human Subjects Act (WMO) is not applicable. The 
PARADIGM study received a ‘non-WMO’ declaration from 
the Medical Ethics Committee of the Netherlands Cancer 
Institute - Antoni van Leeuwenhoek hospital, waiving 
individual patient consent. All data and material used are 
stored in a coded way. Study results will be presented at 
international (breast cancer) conferences and published in 
peer-reviewed, open-access journals.
IntroduCtIon
Breast cancer research has increased over 
the last few decades and led to the develop-
ment and implementation of multiple novel 
(neo) adjuvant systemic treatment modalities. 
The development of these treatment modali-
ties came at a price, with both treatment and 
developmental costs skyrocketing in recent 
strengths and limitations of this study
 ► Large cohort of adjuvant systemic treatment-naive 
patients, ideal for answering prognostic questions
 ► Clinical data were derived from the Netherlands 
Cancer Registry, a large prospective registry with 
reliable data on many clinical variables.
 ► Cause of death is unknown, as a result, breast 
cancer-specific survival cannot be addressed.
 ► Adjuvant treatment allocation in the 1990s was 
based on nodal status; our cohort of untreated 
patients consists of mainly node negative patients, 
results are therefore not generalisable to young 
patients with node positive disease.
group.bmj.com on November 21, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Dackus GMHE, et al. BMJ Open 2017;7:e017842. doi:10.1136/bmjopen-2017-017842
Open Access 
years. Biomarkers predicting sensitivity or resistance for 
these treatments have been developed in parallel, enabling 
the optimal selection of patients for treatment. Clinical 
and genetic prognosticators, on the other hand, have 
been developed to avoid overtreatment and associated 
side effects among patients who do not require systemic 
treatment, thereby reducing unnecessary costs. These prog-
nosticators are usually established and validated in relatively 
small patient populations, often including patients who 
received adjuvant systemic treatment.1 Systemic treatment 
is likely to change the natural course of disease in a signif-
icant proportion of patients; prognostic models based on 
treated patients might therefore produce unreliable risk 
estimates. Moreover, most prognosticators are tailored 
towards a specific patient subset, limiting both their appli-
cability and overall prognostic ability.
Young women diagnosed with breast cancer ≤40 years 
have not, or only sporadically, been included in studies 
establishing and validating prognostic models.1 Breast 
cancers in young women differ from those in older 
women, both genetically and clinicopathologically.2–4 
They are more often hereditary, larger in size, high grade, 
oestrogen receptor (ER) and progesterone receptor (PR) 
negative, human epidermal growth-factor receptor 2 
(HER2) positive and express different genes compared 
with breast cancers in older patients.5–8 These unfavour-
able characteristics usually translate into a shorter time 
to distant recurrence and worse overall survival (OS).9 
It is therefore not surprising that risk estimates derived 
from patient series of older women produce unreliable 
and inconsistent results for young breast cancer patients. 
Adjuvant!Online, for instance, was reported to overesti-
mate OS in 4%–30% of young patients.1 10 The realisation 
that young women do worse compared with their older 
counterparts has, in the absence of reliable prognostic 
means, led to the incorporation of age in current treat-
ment guidelines. Early guidelines recommended adju-
vant systemic therapy for patients with nodal involvement 
only.11 At the fifth international conference of the Inter-
national Consensus Panel on the Treatment of Primary 
Breast Cancer, in 1995, it was acknowledged that patients 
with a young age at diagnosis were considered to have a 
high risk of recurrence, although an exact age threshold 
was not defined.12 It was not until the next meeting in 
1998 that age was accepted as a factor that influences 
treatment decision-making.13 Currently, Dutch guidelines 
recommend systemic treatment for all women diagnosed 
with breast cancer aged <35 years with tumours any size, 
except for those with histological grade 1, provided that 
these tumours are ≤1 cm in diameter.14 In the Nether-
lands, this approach led to a four-fold increase in adju-
vant systemic therapy use in young breast cancer patients 
between 1990 and 2006.15
Although the crude incidence ratio’s from the Nether-
lands Cancer Registry (NCR) show an increase in breast 
cancer incidence from 20.08/100 000 women aged 15–39 
years in 1989 to 27.18/100 000 in 2015 for the same 
age groups,16 the number of breast cancer-specific deaths 
in women 15–39 years decreased from 3.79/100 000 in 
1989 to 2.12/100 000 in 2015.16 This decrease in overall 
mortality might be caused by the increased use of (more 
effective) adjuvant systemic therapies and preventive 
measures taken for BRCA germline mutation carriers. In 
addition, an increased breast cancer awareness among 
young women, leading to earlier tumour detection in 
a group of patients that are not eligible for the regular 
national breast cancer screening programme, inviting 
only 50–75-year olds, may have contributed to the better 
outcome of young breast cancer patients as well.
Although their breast cancers are more aggressive in 
general, a large proportion of young patients have a favour-
able prognosis and do not require adjuvant systemic therapy 
following locoregional treatment.17 The current dilemma is 
that we cannot tell upfront which patient is ‘low risk’ and 
which patient is ‘high risk’. Adjuvant systemic treatment of 
‘low risk’ young women is considered overtreatment and 
might induce certain age-related side effects, for instance 
ovarian suppression and the emergence in time of second 
primary malignancies, while requiring specific measures 
such as fertility preservation.9 To reduce the overtreat-
ment of young breast cancer patients, we need accurate 
prognosticators which are able to discriminate patients 
with an extremely favourable prognosis from those with 
a less favourable prognosis. To do so, a large cohort of 
systemic treatment naive patients is mandatory. To that end 
the PAtients with bReAst cancer DIaGnosed preMenopaus-
ally (PARADIGM) initiative was established.
MEthods
objectives
PARADIGM started in 2012 as part of the Netherlands 
Breast Cancer Project (NBCP). NBCP aims to become the 
population-based counterpart of the Early Breast Cancer 
Trialists’ Collaborative Group, containing population 
based data from the NCR combined with tissue banking. 
PARADIGM entirely focuses on the prognostication of 
young (≤40 years at diagnosis) breast cancer patients. 
Therefore, only women who have not received (neo)adju-
vant systemic or hormonal treatment will be included. 
PARADIGM has set the following initial objectives:
 ► To estimate the true prognosis of breast cancers arising in 
women ≤40 years at diagnosis. The PARADIGM cohort 
will contain full clinical and long-term follow-up 
data of all young, Dutch adjuvant systemic treatment 
naive breast cancer patients diagnosed between 
1989 and 2000. Such a cohort is ideal for answering 
prognostic questions since outcome is known in the 
absence of systemic treatment effects.
 ► To develop a combined clinicomolecular prognosticator for 
the triple-negative (TN) patient subset, using clinical char-
acteristics combined with the differences in gene expression 
between patients with varying outcomes (OS, Recurrence 
Free Survival). The TN patients will be used as a proof 
of principle since they form an ideal group of patients 
because of their virtually non-existent recurrence 
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rates after 10 years.18 When successful, this approach 
will be expanded to the other immunohistochemical 
breast cancer subtypes.
 ► To establish an integrated online image database platform for 
the pathological revision of all cases. The established data-
base may be used for future teaching and research 
purposes.
Numerous research questions can be answered with a 
cohort like PARADIGM. Therefore, after concluding the 
above-mentioned initial phase of data and tissue acquisi-
tion, we will seek funding to:
 ► Develop prognostic models directly derived from the image 
data using deep learning approaches.19 20
 ► Estimate the prognostic performance of established clinical 
and molecular prognosticators on breast cancer patients ≤40 
years.
 ► Estimate the prognosis of women with breast cancer during 
pregnancy in the absence of adjuvant systemic treatment.
 ► Find drivers and potentially actionable mutations of breast 
cancers arising in young women for the development of novel 
targeted therapies.
Patient selection and sample collection
Patients for the PARADIGM study have been selected 
through collaboration with the NCR. The NCR is a popu-
lation-based prospective cancer registry, with nationwide 
coverage since 1989. The NCR registers all newly diag-
nosed, pathologically confirmed malignancies in the 
Netherlands. Detailed information on patient, tumour 
and treatment characteristics are collected from hospital 
records by trained registrars. For PARADIGM, all 3,525 
(neo)adjuvant systemic treatment-naive breast cancer 
patients ≤40 years, diagnosed between 1989 and 2000 with 
non-metastatic, primary invasive, histologically proven, 
TanyNanyM0 tumours have been selected. In this cohort, 
lymph node-negative patients are over-represented since 
adjuvant treatment allocation in the ‘90s was mostly based 
on nodal status.
OS data are available and yearly verified through linkage 
with the municipality population register; cause of death 
however is unknown. Recurrence data are not systemat-
ically recorded by the NCR. Therefore, NCR registrars 
will go back to check the individual hospital records of 
all patients to complete missing information as well as 
data on disease recurrence (local, regional, distant) and 
secondary primaries.
Patients identified by the NCR will be coupled anony-
mously to the nationwide pathology registry in The Neth-
erlands (PALGA)21 by a trusted third party to obtain tissue 
specimens. We aim to collect formalin fixed paraffin 
embedded (FFPE) blocks from normal tissues, tumours, 
lymph nodes and lymph node metastases whenever avail-
able. Based on previous experience, we expect to be able 
to retrieve tissue samples for >75% of patients.
If we want to assess the prognosis of treatment-naive 
women with breast cancer during pregnancy, a linkage 
with either Statistics Netherlands or the Dutch Data 
Protection Authority is mandatory since information 
pertaining to pregnancies and their outcome are not 
registered by the NCR.
Pathological and molecular characterisation
Fresh slides will be cut and stained with haematoxylin 
and eosin (H&E), from all FFPE blocks collected, for 
two reasons. First, old H&E slides often do not repre-
sent the remaining tissue in a block. Second, over the 
years slide quality may deteriorate complicating proper 
digitalisation.
All slides will be scanned onto the online trait Enhanced 
Pathology Image Sharing (tEPIS) system using the Philips 
ultrafast scanner 1.6.1.3 RA (Philips, Amsterdam, The 
Netherlands) or Nanozoomer XR C12000-21/−22 (Hama-
matsu photonics, Hamamatsu, Shizuoka, Japan). The 
tEPIS system is an online image platform for the sharing of 
whole slide pathology images among both researchers and 
pathologists.22 The images on tEPIS can be integrated on 
a case-by-case basis in electronic case report forms (eCRF) 
using a link. These eCRFs will be specifically developed 
for PARADIGM on the web-based OpenClinica database 
(OpenClinica, Waltham, Massachusettes, USA).23 A total 
of 16 specialised European breast pathologists agreed 
to revise cases (figure 1) and enter data in OpenClinica. 
Pathologists will be given data manager rights, in such a 
way they can be treated as unique study sites, blinding them 
for the cases and scores of other pathologists. Items scored 
will be tumour cell percentage, histological subtype, density 
of tumour infiltrating lymphocytes, histological grade and 
the presence of lymphovascular invasion, pushing border, 
fibrotic focus, central necrosis, carcinoma in situ, normal 
tissue and lymph node (metastases) (see online supple-
mentary table 1).
Tissue microarrays (TMA) will be constructed in dupli-
cate, using the TMA Grandmaster (3DHistech, Budapest, 
Hungary), whenever sufficient tumour tissue is available 
according to the H&E slides. When blocks do not fit in the 
TMA Grandmaster, manual non-duplicated TMAs will be 
constructed. Three 0.6 mm cores from the tumour centre 
and periphery will be used per patient, with a maximum 
of 59 patients per Grandmaster TMA or 55 patients in case 
of manual TMAs. Immunohistochemistry (IHC) for ER, 
PR and HER2 will be performed on TMA slides using the 
Ventana BenchMark ULTRA (Ventana Medical Systems, 
Basel, Switzerland) to derive clinical immunohistochem-
ical breast cancer subtypes.24 Whole slides will be cut and 
stained in case insufficient tumour material is present for 
TMA construction. Thresholds for ER and PR tumour 
positivity are set at ≥10% cells staining positive. For HER2, 
both IHC and silver in situ hybridisation (SISH) will be 
performed. Tumours will be considered positive on IHC 
if a strong, complete membranous staining in >10% of 
tumour cells (IHC-3+) is present. Tumours will be consid-
ered positive for HER2 SISH if on average seven or more 
HER2 copies are present in the nucleus (SISH low and 
SISH high level amplified). Tumours scoring positive for 
at least one of the two modalities (IHC or SISH) will be 
considered HER2 positive.
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For the triple-negative patients, RNA will be isolated using 
the AllPrep DNA/RNA isolation kit (QIAGEN, Hilden, 
Germany), according to manufacturer’s protocol. By using 
the AllPrep method, both RNA and DNA are isolated in 
the same instance using only 5 to 10 10µm tumour slides, 
depending on tumour size. Library preparation for RNA 
sequencing (RNAseq) will be conducted using the TruSeq 
RNA Access Kit (Illumina, San Diego, California, USA), 
developed to capture coding RNA sequences of RNA isolated 
from FFPE. RNAseq will be performed at the Genomics 
Core Facility of the Netherlands Cancer Institute.25 Suffi-
cient DNA and RNA will be left for future molecular char-
acterisation and will be stored in the PARADIGM biobank at 
the Core Facility Molecular Pathology & Biobanking of the 
Netherlands Cancer Institute.
Ethical considerations
The PARADIGM initiative will use observational data from 
the NCR and left over archival patient material. All data and 
material on the young breast cancer patients involved in this 
study will be used in a coded way. Neither interventions nor 
active recruitment of study participants will take place within 
PARADIGM. As a result, the Dutch law on Research Involving 
Human Subjects Act (WMO) is not applicable. Therefore, 
the PARADIGM study received a ‘non-WMO’ declaration 
from the Medical Ethics Committee of the Netherlands 
Cancer Institute - Antoni van Leeuwenhoek hospital (NKI), 
waiving individual patient consent, on 31 October 2012 (PTC 
12.1489/NBCP project). In addition, approval from the NKI 
translational research board (TRB) was obtained. The TRB 
oversees that the Codes of Conduct for data and tissue, jointly 
published by the Dutch Federation of Biomedical Scientific 
Societies, the Royal Dutch Medical Association and several 
patient groups,26 are adhered to by the respective researchers.
dIsCussIon
The PARADIGM project is the largest collection of young, 
adjuvant systemic treatment-naive breast cancer patients 
with long-term follow-up. This project provides us with a 
unique opportunity to study the natural course of breast 
cancer outcome in the absence of adjuvant systemic treat-
ment. This will form the basis for testing, validating and 
improving current prognosticators, since most of them 
were not validated in young breast cancer patients before.
Furthermore, knowing the disease course in the absence 
of systemic treatment will enable us to discriminate patients 
with a very favourable prognosis from those with a less 
favourable prognosis. The clinical and molecular differences 
between these two patient groups will be used to establish a 
prognosticator specifically tailored towards young TN breast 
cancer patients. PARADIGM thus aims to reduce overtreat-
ment of young breast cancer patients through adequate 
prognostication.
Figure 1 PARADIGM workflow. All (neo)adjuvant systemic treatment-naive breast cancer patients ≤40 years, diagnosed 
between 1989 and 2000 with non-metastatic, primary invasive, histologically proven, TanyNanyM0 tumours have been selected 
through the Netherlands Cancer Registry, 3,525 patients in total.1 These patients will be linked to PALGA (Dutch Surgical 
pathology Registry),2 if linkage is possible formalin-fixed paraffin-embedded tissue specimens will be requested from the 
respective Dutch pathology laboratory.3 New slides will be cut, H&E stained and digitalised.4 When all available tissues for a 
patient are digitalised, the patient’s case will be uploaded to the online digital imaging platform tEPIS. The images will be linked 
on a case-by-case (patient-by-patient) basis to the online PARADIGM database in OpenClinica. A patient case will be appointed 
to one of 16 specialised breast pathologists who help revise the PARADIGM cases according to the current standard.5 
Pathologists will review the slides in tEPIS and fill out the items asked (see online supplementary table 1) in the PARADIGM 
OpenClinica electronic case report form.6 PARADIGM: PAtients with bReAst cancer DIaGnosed preMenopausally; tEPIS: trait 
Enhanced Pathology Image Sharing.
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A large part of the project is dedicated to tissue retrieval 
and pathological characterisation of all the tumours diag-
nosed. To this end, a digital revision pipeline was estab-
lished, integrating the tEPIS viewer and an OpenClinica 
based database. This approach has several advantages 
over a conventional, hands-on microscopy approach. For 
instance, it is not necessary to send around slides with 
the chance of them getting lost or broken. Digitalising 
all slides enables pathologists to work on the project from 
every physical location, even from outside of the hospital, 
as long as there is a computer with decent internet 
connection available. Sharing slides with pathologists 
over the internet is easy, secure and it even saves patient 
material by making better use of already available tissues. 
Digitalised H&E slides remain stable over time and can be 
shared with other researchers over and over again without 
having to cut new slides. The coupling of an online viewer 
and database limits the amount of errors made because 
the case-by-case linkage of images to CRFs cannot be 
interchanged. The OpenClinica–tEPIS set-up may well 
serve as an example for similar large studies, irrespective 
of the disease being studied. In addition, the availability 
of large pathologically annotated digitalised H&E data-
sets with paired clinical data could be used for teaching 
purposes and the application of state-of-the-art machine 
learning techniques to derive prognostic classifiers.
Although revisions go faster because sharing digital slides 
is easier and more (remote) pathologists can be reached, 
processing blocks and slides remains a time-consuming 
endeavour. Depending on the scanner used, it takes between 
45 and 60 seconds to digitalise a tissue piece measuring 
15 mm×15 mm. After the scanned images are JPEG 
compressed, the file size (one slide) averages 1 gigabyte (GB) 
(spread 50 megabyte-8 GB). Scanning slides and doing the 
necessary quality checks requires many person hours, special-
ised equipment and information technology(IT) infrastruc-
ture to host, store and access all slides. The in-depth genetic 
characterisation of all TN cases through sequencing will pose 
further data storage and privacy challenges.
Pathologists are also faced with new challenges using digi-
talised H&E slides rather than glass slides. Digital revisions 
may take a little more time, depending on network speed and 
familiarity with the system. In addition, mitoses counting on 
(digital) whole slide images depends on image quality and 
is considered more challenging compared with glass slides.27 
Finding expert pathologists motivated to participate free of 
charge and keeping them engaged is a well-known problem 
and might be challenging within PARADIGM as well.28
The PARADIGM patient cohort could be different from 
young breast cancer patients diagnosed nowadays due to 
changes in breast cancer awareness, environmental factors 
and lifestyle, like a higher body mass index, later age of 
first child birth, fewer children and less/shorter periods 
of breast feeding. In addition, the proportion of lymph 
node-positive patients in PARADIGM is probably going to 
be small, since they were considered prognostically unfa-
vourable in the ‘90s and usually received adjuvant systemic 
treatment.
Lastly, finding adequate funding for research projects is 
always challenging. The historic nature of this study and 
the delicate subject of prognosis-driven treatment reduc-
tion for young breast cancer patients have made funding 
particularly difficult. Since correctly assessing a patient’s 
prognosis might be cheaper and hence cost-effective over 
a one-size-fits-all treatment, practice-changing studies like 
the PARADIGM initiative should be of great interest to 
governments and policy-makers, for its research, innova-
tion and  teaching purposes.
ConClusIon
The PARADIGM initiative aims to reduce the overtreat-
ment of young (≤40 years) breast cancer patients by the 
improvement of established and development of novel 
prognosticators in a large group of adjuvant systemic 
treatment-naive patients. The clinical and molecular 
characterisation of young women diagnosed with breast 
cancer will fill in current gaps in prognostication and 
deepen our understanding of breast cancer in women 
of this age group. The development of a prognostic tool 
specifically tailored to TN patients will be the first step 
towards personalised prognostication of young breast 
cancers. This approach will be expanded to the other 
intrinsic subtypes as well in the future. The tEPIS/Open-
Clinica application that was developed can be used for 
extensive research collaborations and may well serve as an 
example for similar large studies in other tumour types 
and non-oncological diseases.
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